Phaseline

Companies › Vaxcyte

Vaxcyte: clinical trials, targets and expected readouts

2 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 3, 1 Phase 1; Infectious disease, Vaccines; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VAX-31 (low dose)
31 valent pneumococcal conjugate vaccine
UNKNOWNPhase 3Pneumococcal Disease; Pneumococcal VaccinesMar 2027
VAX-A1
Vaccine
–Phase 1Group A Streptococcal InfectionDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07284654VAX-31 (low dose)Phase 3Pneumococcal DiseaseInfectious diseaseSep 2026
NCT07425392VAX-31 (low dose)Phase 3Pneumococcal VaccinesVaccinesMar 2027
NCT07365826VAX-31 (low dose)Phase 3Pneumococcal DiseaseInfectious diseaseMar 2027
NCT07616934VAX-A1Phase 1Group A Streptococcal InfectionInfectious diseaseDec 2027
NCT06720038VAX-31 (low dose)Phase 2Pneumococcal VaccinesVaccinesDec 2027
NCT06720038VAX-31 (low dose)Phase 2Pneumococcal VaccinesVaccinesDec 2027
NCT06720038VAX-31 (low dose)Phase 2Pneumococcal VaccinesVaccinesDec 2027
NCT06720038VAX-31 (low dose)Phase 2Pneumococcal VaccinesVaccinesDec 2027

From the company's SEC filings

Cash and short-term investments of $1.3bn on 2026-09-30; operating cash outflow about $989m a year; runway about 16 months at that burn, to Jan 2028; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

UNKNOWN (1)

Companies with the same targets

General Oncology Gilead Sciences Iterum Therapeutics, International Colgate Palmolive Zhejiang Raygene Pharmaceuticals

Companies built like this

Cellid Dynavax Technologies Guangzhou Patronus Biotech SK Bioscience Inventprise

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.